FDA clears drug for metastatic pancreatic cancer

The FDA has approved a new medication called Onivyde, developed by Ipsen, for patients with aggressive, metastatic pancreatic adenocarcinoma. This approval followed positive results from a phase 3 trial involving 770 patients. Onivyde, an infusion administered every two weeks, extended patients' survival by a median of 11.1 months compared to other treatments. Common side effects include fatigue, nausea, vomiting, decreased appetite, abdominal pain, and diarrhea. Despite being designated as an "orphan drug" by the FDA, meaning it's for rare conditions, Onivyde has shown significant efficacy in improving patient outcomes.